Ketamine Effects on Learning In Eating Disorders

Part of paid clinical trials in San Francisco, California.

Sponsor
Amanda Downey, MD
Study ID
NCT06736769
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Anorexia Nervosa
  • Atypical Anorexia Nervosa

Eligibility Criteria

Sex
ALL
Age
16 Years - 26 Years
Healthy Volunteers
Not accepted

Interventions

  • Ketamine infusion — DRUG
    Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.

Study Details

This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.

Key Dates

Start date
Jun 5, 2025
Status verified
Jun 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ketamine Infusion

Primary Outcome Measure

Mean Change From Baseline in Reversal Learning [ Time Frame: Day 2, Day 4 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94158-

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies